Nanocarriers made from non-ionic surfactants or natural polymers for pulmonary drug delivery

Current Pharmaceutical Design

Volumn 22, Issue 22, 2016, Pages 3324-3331

  Carter, K C ^a   Puig Sellart, M ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Drug delivery systems; Nanoparticles; Non ionic surfactant vesicles; Pulmonary

Indexed keywords

ALBUMIN; ALGINIC ACID; CARRAGEENAN; CHITOSAN; COLLAGEN; GLUTEN; HYALURONIC ACID; NANOCARRIER; NANOPARTICLE; NATURAL PRODUCT; NONIONIC SURFACTANT; POLYMER; STARCH; BIOLOGICAL PRODUCT; DRUG CARRIER; SURFACTANT;

ARTICLE; DRUG FORMULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INHALER; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; SPRAY DRYING; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; LUNG; METABOLISM;

ANIMALS; BIOLOGICAL PRODUCTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; NANOPARTICLES; POLYMERS; SURFACE-ACTIVE AGENTS;

EID: 84975686798     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160418121700     Document Type: Article

References (69)

1. Pulmonary Drug Delivery Systems Market Expected to Reach USD 28.7 Billion Globally in 2019; Transparency Market Research. Available from: (www.transparencymarketresearch.com/ pulmonary-drug-delivery-systems.html).
2. Colombo P, Traini D, Buttini F. Inhalation Drug Delivery. First ed. Chichester: West Sussex 2012.
3. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir Med 2003; 97: 382-7.
4. Lucangelo U, Pelosi P, Walter AZ, Aliverti A. Respiratory System and Artificial Ventilation. First ed. New York: Springer 2008.
5. Clarke SW. Inhaler therapy. Q J Med 1988; 67: 355-68.
6. Byron R. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci 1986: 7: 433-8.
7. Asking L, Olsson B. Calibration at different flow rates of a multistage liquid impinge. Aerosol Sci Technol 1997; 27: 39-49.
8. Zanen P, Go LT, Lammers WJ. The optimal particle size for α-adrenergic aerosols in mild asthmatics. Int J Pharm 1994; 107: 211-7.
9. Johnson MA, Newman SP, Bloom R, Talaee N, Clarke SW. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. Chest 1989; 96: 6-10.
10. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74.
11. Dolovich M, Sanchis J, Rossman C, Newhouse M. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol 1976; 40: 468-71.
12. Nahar K, Gupta N, Gauvin R, et al. In vitro, in vivo and ex vivo models for studying particle deposition and drug absorption of inhaled pharmaceuticals. Eur J Pharm Sci 2013; 49: 805-18.
13. Hillery AM, Lloyd AW, Swarbrick J. Drug delivery and targeting for pharmacists and pharmaceutical scientists. First ed. UK: Taylor & Francis Library 2001.
14. Hu T, Wang J, Shen Z, Chen J. Engineering of drug nanoparticles by HGCP for pharmaceutical applications. Particulogy 2008; 6: 239-51.
15. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377: 1032-45.
16. Lavorini F, Fontana GA, Usmani OS. New inhaler devices-The good, the bad and the ugly. Respiration 2014; 88: 3-15.
17. European Pharmacopeia, 2.9.18 Preparations for inhalation: aerodynamic assessment of fine particles. Prep Inhal 2005; 5.1: 2799-811.
18. Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. Available at (http//www.pharmacopeia.cn/v29240/usp29nf 24s0_c601_viewall.html).
19. Boer AH, Gjaltema D, Hagedoorn P, Frijlink HW. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharm 2002: 249: 219-31.
20. Triballier K, Dumouchel C, Cousin J. A technical study on the Spraytec performances: influence of multiple light scattering and multi-modal drop-size distribution measurements. Exp Fluids 2003; 35: 347-56.
21. Pilcer G, Vanderbist F, Amighi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int J Pharm 2008: 358: 75-81.
22. Cheng Y, Irshand H, Kuehl P, Holmes T, Sherwood R, Hobbs C. Lung deposition of droplet aerosols in monkeys. Inhal Toxicol 2008; 11: 1029-36.
23. Oller AR, Oberdörster G. Incorporation of particle size differences between animal studies and human workplace aerosols for deriving exposure limit values. Regul Toxicol Pharmacol 2010; 57: 181-94.
24. Miller FJ, Mercer RR, Crapo JD. Lower respiratory tract structure of laboratory animals and humans: dosimetry implications. Aerosol Sci Technol 1993; 18: 257-61.
25. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006: 58: 1030-60.
26. Cryan SA, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev 2007; 59: 1133-51.
27. Schlesinger RB. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J Toxicol Environ Health 1985; 15: 197-214.
28. Patel B, Gauvin R, Absar S, et al. Computational and bioengineered lungs as alternatives to whole animal, isolated organ, and cell-based lung models. Computational and bioengineered lungs as alternatives to whole animal, isolated organ, and cell-based lung models Computational and bioengineered lungs as alternatives to whole animal, isolated organ, and cell-based lung models. Am J Physiol Lung Cell Mol Physiol 2012; 303: 733-47.
29. Newman S. Scintigraphic assessment of therapeutic aerosols. Crit Rev Ther Drug Carrier Syst 1993; 10: 65-109.
30. Pérez-Campaña C, Gómez-Vallejo V, Puigivila M, et al. Assessing lung inflammation after nanoparticle inhalation using 2-deoxy-2-[18F]Fluoro-d-glucose positron emission tomography imaging. Mol Imaging Biol 2014; 16: 264-73.
31. Thompson R, Finlay W. Using MRI to measure aerosol deposition. J Aerosol Med Pulm Drug Deliv 2012; 25: 55-62.
32. Yi D, Naqwi A, Panoskaltsis-Mortari A, Wiedmann TS. Distribution of aerosols in mouse lobes by fluorescent imaging. Int J Pharm 2012: 426: 108-15.
33. Walia SA, Acharya A. Silica micro/nanospheres for theranostics: from bimodal MRI and fluorescent imaging probes to cancer therapy. Beilstein J Nanotechnol 2015: 6: 546-58.
34. Alsaadi M, Italia JL, Mullen AB, et al. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection. J Control Release 2012: 160: 685-91.
35. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013; 38: 792-804.
36. Collins M, Carter K, Baillie A, O’Grady J. The distribution of free and non-ionic vesicular sodium stibogluconate in the Dog. J Drug Target 1993: 1: 133-42.
37. Kraft JC, Freeling JP, Wang Z, Ho RJY. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. J Pharm Sci 2014; 103: 29-52.
38. Moreno-Sastre M, Pastor M, Salomon CJ, Esquisabel A, Pedraz JL. Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy. J Antimicrob Chemother 2015; 70: 2945-55.
39. Pham D.D, Fattal E, Tsapis N. Pulmonary drug delivery systems for tuberculosis treatment. Int J Pharm 2015; 478: 517-29.
40. Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): Physical and pharmaceutical chemistry. Adv Colloid Interface Sci 1995; 58: 1-55.
41. Alvar J, Velez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7: e35671.
42. Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis 2012; 55: 543-50.
43. Rijal S, Ostyn B, Uranw S, et al. Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 2013; 56: 1530-8.
44. Carter KC, Dolan TF, Alexander J, Baillie AJ, McColgan C. Characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J Pharm Pharmacol 1989; 2: 87-91.
45. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997; 41: 2089-92.
46. Carter KC, Mullen AB, Sundar S, Kenney RT. Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob Agents Chemother 2001; 45: 3555-9.
47. Nieto J, Alvar J, Mullen AB, et al. Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals. Antimicrob Agents Chemother 2003; 47: 2781-7.
48. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997; 41: 2089-92.
49. Williams D, Mullen AB, Baillie AJ, Carter KC. Comparison of the efficacy of free and non-ionic.-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol 1998; 50: 1351-6.
50. Terzano C, Allegra L, Alhaique F, Marianecci C, Carafa M. Nonphospholipid vesicles for pulmonary glucocorticoid delivery. Eur J Pharm Biopharm 2005; 59: 57-62.
51. Stein SW, Sheth P, Hodson PD, Myrdal PB. Advances in metered dose inhaler technology: Hardware development. AAPS Pharm-SciTech 2014: 15: 326-38.
52. Nagarajan U, Kawakami K, Zhang S, Chandrasekaran B, Unni Nair B. Fabrication of solid collagen nanoparticles using electrospray deposition. Chem Pharm Bull 2014; 62: 422-8.
53. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 2012: 157: 168-82.
54. Choi SH, Byeon HJ, Choi JS, et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 2015; 10: 199-207.
55. O’Shaughnessy J, Gradishar WJ, Bhar P, Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat 2013; 138: 829-37.
56. Grootjans-van Kampen I, Engelfriet PM, van Baal PH. Disease Prevention: Saving Lives or Reducing Health Care Costs? PLoS One 2014; 9: e104469.
57. Minuti G, D’Incecco AF, Cappuzzo F. Current and emerging options in the management of EGFR mutation-positive non-small-cell lung cancer: considerations in the elderly. Drugs Aging 2015: 7: 1-10.
58. Pal A, Talukdar D, Roy A, et al. Nanofabrication of methylglyoxal with chitosan biopolymer: a potential tool for enhancement of its anticancer effect. Int J Nanomed 2015: 10: 3499-518.
59. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006; 1: 297-315.
60. Mizrahy S, Raz SR, Hasgaard M, et al. Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release 2011; 156: 231-8.
61. Pan-In P, Wanichwecharungruang S, Hanes J, Kim AJ. Cellular trafficking and anticancer activity of Garcinia mangostana extractencapsulated polymeric nanoparticles. Int J Nanomed 2014; 9: 3677-86.
62. Ungaro F, d’Emmanuele di Villa Bianca R, Giovino C, et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 2009: 135: 25-34.
63. Sanchez VC, Jachak A, Hurt RH, Kane AB. Biological interactions of graphene-family nanomaterials: an interdisciplinary review. Chem Res Toxicol 2012: 25: 15-34.
64. Hernandez R. Continuous manufacturing: A changing processing paradigm. BioPharm Int 2015: 28: 20-7.
65. Glangchai LC, Caldorera-Moore M, Shi L, Roy K. Nanoimprint lithography based fabrication of shape-specific, enzymaticallytriggered smart nanoparticles. J Control Release 2008: 125: 263-72.
66. Rahimpour Y, Hamishehkar H. Lactose engineering for better performance in dry powder inhalers. Adv Pharm Bull 2012; 2: 183-7.
67. Agarwal R, Singh V, Jurney P, Shi L, Sreenivasan SV, Roy K. Scalable imprinting of shape-specific polymeric nanocarriers using a release layer of switchable water solubility. ACS Nano 2012; 6: 2524-31.
68. Poldervaart MT, Wang H, van der Stok J, et al. Sustained release of BMP-2 in bioprinted alginate for osteogenicity in mice and rats. PLoS One 2013; 8: e72610.
69. Rubin BK. Pediatric aerosol therapy: new devices and new drugs. Respir Care 2011; 56: 1411-21.